SAN ANTONIO, TX — October 7, 2025 — Leads & Copy — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced that sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. In the first nine months of 2025, sales of CyPath® Lung rose 97% over the same period in 2024. The increase reflects growing adoption by Veterans’ hospitals and market expansion in the mid-Atlantic region.
According to Maria Zannes, President and CEO of bioAffinity Technologies, the continued acceleration in CyPath® Lung adoption underscores growing physician confidence in the test to detect lung cancer at its earliest, most treatable stages. Physicians are also impressed by CyPath® Lung’s ability to save patients from unnecessary invasive procedures when the nodule is benign, Zannes said.
The company reported that performance metrics showed similar improvements in the third quarter, including a 77% increase in the number of new patients using CyPath® Lung and greater patient compliance for at-home sample collection and return.
Published patient case studies demonstrate the clinical impact of CyPath® Lung, including:
Detecting Stage 1A lung cancer in patients after other diagnostics suggested a low probability of cancer.
Sparing patients from invasive procedures when the CyPath® Lung result was negative.
Detecting lung cancer earlier in difficult-to-diagnose ground-glass nodules.
According to Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies, the company is immensely proud of the real-world impact CyPath® Lung is having on patients and their families. He added that every early cancer detected means a life that may be saved, and every unnecessary invasive procedure avoided means a patient spared from risk, anxiety and cost, which is why more physicians are adding CyPath® Lung as an essential tool in the diagnostic pathway.
About CyPath® Lung:
CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com.
About bioAffinity Technologies, Inc.:
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Contact:
Maria Zannes, President and CEO of bioAffinity Technologies.
Source: bioAffinity Technologies, Inc.
